Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis
Running title: Elexacaftor & exercise capacity in CF
Adam J. Causer (MSc)a,b, Janis K. Shute (PhD)c, Michael H. Cummings (MD, FRCP)d, Anthony I. Shepherd (PhD)a, Samuel R. Wallbanks (BSc)a, Richard M Pulsford (PhD)e, Victoria Bright (BSc)b, Gary Connett (MD, FRCPCH)b,f, and Zoe L. Saynor (PhD)a,b*.
a School of Sport, Health and Exercise Science, Faculty of Science and Health, University of Portsmouth, Portsmouth, UK.
b Cystic Fibrosis Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
c School of Pharmacy and Biomedical Sciences, Faculty of Science and Health, University of Portsmouth, Portsmouth, UK.
d Department of Diabetes and Endocrinology, Queen Alexandra Hospital, Portsmouth, UK.
e Department of Sport and Health Sciences, College of Life and Environmental Science, University of Exeter, Exeter, UK.
f National Institute for Health Research, Southampton Biomedical Research Centre, Southampton Children’s Hospital, UK
* Correspondence to Dr. Z. L. Saynor, School of Sport, Health and Exercise Science, Faculty of Science and Health, University of Portsmouth, Portsmouth, Hampshire, UK, PO1 2ER.
Tel: +44 (0)2392 843080
Email: zoe.saynor@port.ac.uk
Keywords: Elexacaftor-tezacaftor-ivacaftor; cardiorespiratory fitness; CFTR modulator therapy; cystic fibrosis-transmembrane conductance regulator; peak oxygen uptake; respiratory disease.